Literature DB >> 10490839

The transmembranal and cytoplasmic forms of protein tyrosine phosphatase epsilon physically associate with the adaptor molecule Grb2.

H Toledano-Katchalski1, A Elson.   

Abstract

The protein tyrosine phosphatase Epsilon (PTPepsilon) gene gives rise to two physiologically-distinct protein products - a transmembranal, receptor-like form and a cytoplasmic, non-receptor form. Previous studies have suggested a link between expression of transmembranal PTPepsilon and transformation of mouse mammary epithelium specifically by ras or neu, although little is known about the underlying molecular mechanisms; cytoplasmic PTPepsilon is believed to function mainly in hematopoietic tissues. As part of our efforts to understand PTPepsilon function at the molecular level, we demonstrate here that both forms of PTPepsilon associate with the adaptor molecule Grb2 in vivo. Binding is mediated by the SH2 domain of Grb2; this domain binds exclusively to the carboxy-terminal phosphotyrosine of cytoplasmic PTPepsilon(Y638), and probably to additional phosphotyrosine residues in transmembranal PTPepsilon. Through its SH2 domain, Grb2 can constitutively associate with transmembranal PTPepsilon in mammary tumors initiated by ras or neu, and can be induced to associate with cytoplasmic PTPepsilon in Jurkat T-cells following stimulation of T-cell receptor signaling by pervanadate. These findings indicate that tyrosine phosphorylation of PTPepsilon and subsequent binding to Grb may link this phosphatase to downstream events which transduce signals from the cell membrane to its interior.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490839     DOI: 10.1038/sj.onc.1202883

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Comparative study of protein tyrosine phosphatase-epsilon isoforms: membrane localization confers specificity in cellular signalling.

Authors:  J N Andersen; A Elson; R Lammers; J Rømer; J T Clausen; K B Møller; N P Møller
Journal:  Biochem J       Date:  2001-03-15       Impact factor: 3.857

2.  Protein tyrosine phosphatase epsilon regulates integrin-mediated podosome stability in osteoclasts by activating Src.

Authors:  Shira Granot-Attas; Chen Luxenburg; Eynat Finkelshtein; Ari Elson
Journal:  Mol Biol Cell       Date:  2009-08-19       Impact factor: 4.138

3.  Adaptor protein GRB2 promotes Src tyrosine kinase activation and podosomal organization by protein-tyrosine phosphatase ϵ in osteoclasts.

Authors:  Einat Levy-Apter; Eynat Finkelshtein; Vidyasiri Vemulapalli; Shawn S-C Li; Mark T Bedford; Ari Elson
Journal:  J Biol Chem       Date:  2014-11-07       Impact factor: 5.157

4.  Hypomyelination and increased activity of voltage-gated K(+) channels in mice lacking protein tyrosine phosphatase epsilon.

Authors:  A Peretz; H Gil-Henn; A Sobko; V Shinder; B Attali; A Elson
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

5.  PTPepsilon has a critical role in signaling transduction pathways and phosphoprotein network topology in red cells.

Authors:  Lucia De Franceschi; Andrea Biondani; Franco Carta; Franco Turrini; Carlo Laudanna; Renzo Deana; Anna Maria Brunati; Loris Turretta; Achille Iolascon; Silverio Perrotta; Ari Elson; Cristina Bulato; Carlo Brugnara
Journal:  Proteomics       Date:  2008-11       Impact factor: 3.984

6.  Quantitative time-resolved phosphoproteomic analysis of mast cell signaling.

Authors:  Lulu Cao; Kebing Yu; Cindy Banh; Vinh Nguyen; Anna Ritz; Benjamin J Raphael; Yuko Kawakami; Toshiaki Kawakami; Arthur R Salomon
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

7.  Conserved Motifs within Hepatitis C Virus Envelope (E2) RNA and Protein Independently Inhibit T Cell Activation.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Thomas M Kaufman; Jack T Stapleton
Journal:  PLoS Pathog       Date:  2015-09-30       Impact factor: 6.823

8.  Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; M Meleah Mathahs; Warren N Schmidt; Thomas M Kaufman; Jack T Stapleton
Journal:  PLoS Pathog       Date:  2017-02-24       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.